Taking together our data suggesting that the treatment of patients with poor responsiveness to TB therapy may be needed to include IFN-γ as adjuvant therapy after full characterization of immunopathologic mechanisms in these and in other more multidrug-resistant TB patients. Here, IFNG is linked to tuberculosis.